A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood

NCT05380947 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: BI 1810631 - trial formulation 1 (TF1)
DRUG: BI 1810631 - new formulation (NF)
DRUG: Rabeprazole sodium

Sponsor

Boehringer Ingelheim